Screening Of Tumor Markers For Lung Cancer Based On Metabolomics

Background and objective:Lung Cancer is one of the most common malignant tumors in the world today.So far,no ideal tumor markers have been found for the early diagnosis of lung cancer.Therefore,it has become a hot spot in lung cancer research to try to explore new biological markers with various new methods.In this study,the metabolomics technology analysis platform was used to find differences in metabolites from blood samples of normal population and lung cancer patients,to find potential tumor diagnostic markers,and to provide new ideas and new methods for the early diagnosis of lung cancer.Methods:Patients admitted to the Department of Respiratory Medicine of the First Affiliated Hospital of Nanchang University from February 2019 to August 2019 due to pulmonary shadow or lung occupying found in physical examination,as well as healthy subjects who went to the Department of Physical Examination during the same period were selected as the research subjects.Blood samples were collected from 25 lung cancer patients and 25 healthy controls.Metabonomics data were analyzed with Metabo Analyst 5.0.Multivariate statistical Analysis method Sparse Partial Least Square-Discriminant Analysis(SPLS-DA)was used to identify potential markers,and internal training data were used for modeling.The t test of the two samples was used to find the metabolites of difference between the two groups.Results:When the Total Ions Chromatogram was identified in serum samples from a selected mass spectrometric database analysis,a total of 178 metabolites with a better matching degree were obtained.Multivariate statistical results showed that the metabolic profiles of lung cancer patients and healthy subjects were significantly different,according to t test(P < 0.05,and FDR < 0.01)and 15 kinds of serum related differential metabolites were found:p-hydroxyphenyllactic acid,Nacetylneuranine,hypoxanthine,3-methyllysine,4-hydroxy-1-3-pyridinylbutanone,5-deoxy-5-methiono-adenosine,L-tyrosine,diurea-acetic acid,proline,citrate,3-amino-3-(4-hydroxyphenyl-propionic acid),isolinyl-leucine,3-hydroxy-2-[(9Z,12)Z)-9,12-Octadecadienoyloxy]propyl2-(Trimethylammonio)Ethylphosphate,galacturonic acid,leucine.Among them,there were 3 kinds of high and low differences between the two samples: p-hydroxyphenyllactic acid,N-acetylneura-minic acid and hypoxanthine.Conclusion:(1)It was found that antihydroxyphenene lactic acid was significantly increased in patients with lung cancer,which may be because tumor cells mainly take glycolysis as the main energy metabolism,and then transformed in the body.N-acetylneurine and subxanthine were significantly reduced in the LC group,which may have some value for screening lung cancer.However,4-hydroxy-1-3pyridine-butylketone and 5-deoxygen-5-methioadenosine need to be further studied to explore its possible biological value.(2)Select patient blood samples based on metabolomics technology,and establish a s PLS-DA model with high sensitivity and specificity,which is conducive to the screening and diagnosis of lung cancer.